← brief for 2026-08-12 · Slowing decline

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Trial No results yet Not peer reviewed

Key takeaways

This early study measures how much of a new drug, eloralintide, gets into the blood and how fast the body clears it. It compares people with reduced kidney function to healthy people. The trial is just starting, so there are no results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Floridian Clinical Research, LLC · Omega Research Orlando LLC

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07426380